Lincoln Pharmaceuticals has informed that pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and amendment thereto (‘Regulations’) and Code of Practices & Procedures for Fair Disclosure of Unpublished Price Sensitive Information adopted by the Company, the Trading Window for dealing in the securities of the Company shall remain closed from October 01, 2024 till 48 hours after the declaration of the Financial Results of the Company, for the quarter ended September 30, 2024. The date of meeting of the Board of Directors, to approve the Financial Results of the Company for the quarter ended September, 2024, will be informed in due course. Accordingly, all Directors, Senior Management Personnel, Promoter and Promoter Group of the Company and its subsidiaries including their Immediate Relatives and other Connected Persons are advised not to trade in securities of the Company during the aforesaid period of closure of trading window.
The above information is a part of company’s filings submitted to BSE.
